Current COVID-19 PAB Statement
The Marfan Foundation, in collaboration with our Professional Advisory Board (PAB), continues to monitor the news regarding COVID-19 and wants to provide updated information for our community. We continue to reaffirm recommendations issued by the Centers for Disease Control and Prevention (CDC) regarding the virus and update our specific information for the Marfan, VEDS, LDS, and related conditions community. Read the latest PAB statement here.
President/CEO Update with Annual Conference Information
After much discussion, we have decided to delay the launch of the 36th Annual Conference site for at least several weeks, based upon latest meeting guidelines in Massachusetts, which will be updated on or before April 5, 2020. We remain optimistic but need to be guided by our overwhelming desire to protect our community. We are also monitoring plans for other rare condition conferences in the same window of time. Read President and CEO Michael Weamer’s latest update here.
Important Medication Statement
Recent reports have raised concerns that ACE inhibitors and angiotensin receptor blockers (ARBs), such as losartan, Irbesartan, valsartan or telmisartan, may increase risks for infection or illness due to infection by COVID-19. We currently do not know if ARBs are harmful or protective in people who are exposed to COVID-19. However, abrupt discontinuation of ARBs can make hypertension worse and may trigger acute arterial dissections in people with heritable vascular diseases. Therefore, we strongly advise that people who take ARBs regularly should continue to take them without interruption. Read full PAB statement here.